Grimm Marc-Oliver, Steinhoff Christine, Simon Xenia, Spiegelhalder Philipp, Ackermann Rolf, Vogeli Thomas Alexander
Department of Urology, Heinrich-Heine University, Düsseldorf, Germany.
J Urol. 2003 Aug;170(2 Pt 1):433-7. doi: 10.1097/01.ju.0000070437.14275.e0.
We determined the long-term outcome in patients with superficial bladder cancer (Ta and T1) undergoing routine second transurethral bladder tumor resection (ReTURB) in regard to recurrence and progression.
We performed an inception cohort study of 124 consecutive patients with superficial bladder cancer undergoing transurethral resection and routine ReTURB (83) between November 1993 and October 1995 at a German university hospital. Immediately after transurethral resection all lesions were documented on a designed bladder map. ReTURB of the scar from initial resection and other suspicious lesions was performed at a mean of 7 weeks. Patients were followed until recurrence or death, or a minimum of 5 years.
Residual tumor was found in 33% of all ReTURB cases, including 27% of Ta and 53% of T1 disease, and in 81% at the initial resection site. Five of the 83 patients underwent radical cystectomy due to ReTURB findings. The estimated risk of recurrence after years 1 to 3 was 18%, 29% and 32%, respectively. After 5 years 63% of the patients undergoing ReTURB were still disease-free (mean recurrence-free survival 62 months, median 87). Progression to muscle invasive disease was observed in only 2 patients (3%) after a mean observation of 61 months.
These data suggest a favorable outcome regarding recurrence and progression in patients with superficial bladder cancer who undergo ReTURB. ReTURB is suggested at least in those at high risk when bladder preservation is intended.
我们确定了接受常规二次经尿道膀胱肿瘤切除术(ReTURB)的浅表性膀胱癌(Ta和T1期)患者在复发和进展方面的长期预后。
我们对1993年11月至1995年10月期间在德国一家大学医院连续接受经尿道切除术和常规ReTURB(83例)的124例浅表性膀胱癌患者进行了一项起始队列研究。经尿道切除术后立即将所有病变记录在设计好的膀胱图上。对初次切除部位的瘢痕及其他可疑病变进行ReTURB,平均时间为7周。对患者进行随访直至复发、死亡或至少5年。
在所有ReTURB病例中,33%发现有残留肿瘤,其中Ta期为27%,T1期为53%,在初次切除部位残留肿瘤的比例为81%。83例患者中有5例因ReTURB结果接受了根治性膀胱切除术。第1至3年的复发风险估计分别为18%、29%和32%。5年后,接受ReTURB的患者中有63%仍无疾病(平均无复发生存期62个月,中位数87个月)。平均观察61个月后,仅2例患者(3%)进展为肌层浸润性疾病。
这些数据表明,接受ReTURB的浅表性膀胱癌患者在复发和进展方面预后良好。建议至少在那些希望保留膀胱的高危患者中进行ReTURB。